Define Ventures Welcomes Former Aetion and Remedy Partners CEO Carolyn Magill as Venture Partner
SAN FRANCISCO, March 11, 2025 /PRNewswire/ — Define Ventures, a leading venture capital firm specializing in early-stage health tech companies, is excited to announce the addition of Carolyn Magill, former CEO of Aetion, as a venture partner. With her extensive experience in scaling companies and driving innovation within the payer, provider, and pharmaceutical sectors, Magill will collaborate with Define founders to propel their companies to new heights and establish them as industry leaders.
Carolyn Magill brings a wealth of knowledge as a seasoned healthcare executive and two-time CEO. Prior to joining Define Ventures, she served as the CEO of Aetion, a platform that converts real-world data into high-quality evidence for crucial healthcare decisions. Magill also led Remedy Partners, a top bundled payments software and services company, and held key positions at Evolent Health and UnitedHealth Group. Her diverse background across various healthcare domains positions her as a valuable asset to guide the next generation of health tech innovators.
Lynne Chou O’Keefe, founder and managing partner at Define Ventures, expressed confidence in Magill’s expertise, particularly in data and AI applications within the pharmaceutical industry. Magill herself highlighted Define Ventures as a hub of innovation in healthcare, where she can leverage her experience to help founders transform ideas into impactful solutions.
In joining Define Ventures, Carolyn Magill complements the existing team of venture partners, including Bruce Broussard, former CEO of Humana, and Frank Williams, co-founder of Evolent Health. Together, they offer a comprehensive range of experience across payer, provider, and pharmaceutical sectors, enhancing Define’s ability to support partner companies effectively.
Define Ventures manages assets worth $800 million and collaborates with companies at various stages of development, from seed to series B. The firm has partnered with over two dozen companies, including Hims & Hers, Unite Us, and Cohere Health, to drive innovation in the health tech space.
About Define Ventures
Define Ventures is a prominent fund specializing in early-stage health tech companies, with $800 million in assets under management. The firm’s high conviction approach involves partnering with companies in their nascent stages to shape the future of healthcare. The team at Define Ventures comprises founders and investors who have built category-defining companies, delivering over $25 billion in exit value.
In conclusion, Define Ventures’ addition of Carolyn Magill as a venture partner underscores the firm’s commitment to fostering innovation in the healthcare industry. With a strong team of industry leaders and a track record of success, Define Ventures is well-positioned to support cutting-edge health tech companies in achieving their full potential. To learn more about Define Ventures, visit www.definevc.com.
